ERBB2 and breast cancer: In endocrine therapy resistant BC, HER-2 mutation frequency was increasing and PI3K/Akt/mTOR signaling pathway is over activated, at this time, neratinib was given to inhibit the HER-2 function of mutation, it can not only effectively control the tumor, but also restore the efficacy of anti-hormone therapy(Croessmann et al. 2019).